⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14422553 | 0.65 | — | — | |
| SCHEMBL7521997 | 0.64 | TSHR (0.35) | — | |
| SCHEMBL2301074 | 0.62 | — | — | |
| SCHEMBL3653848 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL17597680 | 0.61 | BLM (0.41) | — | |
| Hydrochloric Acid SCHEMBL10438113 | 0.61 | BLM (0.41) | — | |
| SCHEMBL3396869 | 0.61 | TSHR (0.36) | — | |
| SCHEMBL990342 | 0.60 | — | — | |
| Hydrochloric Acid SCHEMBL7218922 | 0.60 | BLM (0.38) | — | |
| SCHEMBL9476008 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047201-A | Uracil derivative as AXL and c-MET kinase inhibitors | 亚尼塔公司 | 2018-05-18 | — | — | CN | claimed |
| CN-103958497-B | uracil derivatives as AXL and c-MET kinase inhibitors | 亚尼塔公司 | 2017-09-01 | — | — | CN | claimed |
| EP-4139000-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | Assembly Biosciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022166916-A1 | SUBSTITUTED HETEROARYL DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| CN-110506039-A | Compounds and methods for targeted degradation of androgen receptor | ARVINAS INC | 2019-11-26 | — | — | CN | disclosed |
| CN-105658647-B | The salt of compound | 拜耳医药股份有限公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-108047201-A | Uracil derivative as AXL and c-MET kinase inhibitors | 亚尼塔公司 | 2018-05-18 | — | — | CN | disclosed |
| CN-103958497-B | uracil derivatives as AXL and c-MET kinase inhibitors | 亚尼塔公司 | 2017-09-01 | — | — | CN | disclosed |
| CN-106983751-A | Two ring substituted uracils and application thereof | 拜耳医药股份有限公司 | 2017-07-28 | — | — | CN | disclosed |
| CN-104395310-B | Bicyclic substituted uracils and their use | 拜耳药业股份公司 | 2017-05-03 | — | — | CN | disclosed |
| CN-105980381-A | Substituted uracils and use thereof | 拜耳医药股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-105658647-A | Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid | 拜耳医药股份有限公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-104395310-A | Bicyclic substituted uracils and their use | Bayer Pharma AG | 2015-03-04 | — | — | CN | disclosed |
| CN-103958497-A | Uracil derivatives as AXL and c-MET kinase inhibitors | CEPHALON INC | 2014-07-30 | — | — | CN | disclosed |
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| CN-102482231-A | Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof | Bayer Pharma AG | 2012-05-30 | — | — | CN | disclosed |
| WO-2002090592-A1 | METHOD FOR EVALUATING AND APPLYING AN INDIVIDUAL'S GENETIC CHARACTERISTICS TO DETERMINE RESPONSE TO CARDIOVASCULAR MEDICATION THERAPY | IHC HEALTH SERVICES, INC. (US) | 2002-11-14 | — | — | WO | disclosed |